Effects of Different Anti-Rheumatic Treatments of Arthritis on Antibody Response Following Pneumococcal Vaccination Using Prevenar.

Trial Profile

Effects of Different Anti-Rheumatic Treatments of Arthritis on Antibody Response Following Pneumococcal Vaccination Using Prevenar.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Sep 2015

At a glance

  • Drugs Pneumococcal 7-valent CRM197 vaccine conjugate (Primary) ; Antirheumatics
  • Indications Pneumococcal infections; Rheumatic disorders; Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Acronyms PVA
  • Most Recent Events

    • 23 Sep 2015 Status changed from recruiting to active, no longer recruiting as per info from results published in journal "Arthritis Research and Therapy" 505 patients have been enrolled which is > than planned accrual according to CT.gov [Last updated: November 6, 2013] which is showing status "study is enrolling participants by invitation only".As CT.gov is not recently updated and end date is passed it seems that enrollment has been completed.
    • 06 Nov 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 06 Sep 2011 Planned end date changed from 1 Apr 2009 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top